MetaCap

Recursion Pharmaceuticals Inc. Class A (RXRX)

NASDAQ: RXRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.45-0.27 (-9.93%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

RXRX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.86
52-week range
2.44 – 5.24
Day range
2.44 – 2.76
Volume / Avg
29.80M / 24.47M
Beta
—

52-week range

$2.44$5.24

RXRX stock today

On Nov 20, RXRX ended the session at $2.45, shedding $0.27 (9.93%), versus the S&P 500's 3.70% decline. At this level, RXRX sits near the bottom of its 52-week range of $2.44 to $5.24: 53.2% below the high, set on Jan 22, 2026 and 0.4% above the low. RXRX is down 40.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 41.2%.

Recursion Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.86), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Recursion Pharmaceuticals

Company profile

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Najat Khan Ph.D.
Headquarters
Salt Lake City, UT
Employees
600
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Recursion Pharmaceuticals generated $74.7 million in revenue, up 26.9% from fiscal 2024, its 6th consecutive year of revenue growth. Recursion Pharmaceuticals reported a net loss of $644.8 million, compared with a loss of $463.7 million a year earlier. Gross margin was 5.0% (down from 23.1%) and operating margin -867.9%.

Recursion Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$74.68M$58.84M$44.58M$39.84M$10.18M
Growth+26.92%+32.00%+11.88%+291.46%+156.89%
Net income$-644.76M$-463.66M$-328.07M$-239.48M$-186.48M
EPS (diluted)$-1.44$-1.69$-1.58$-1.36$-1.49

Analyst forecast

Forecast

Consensus (7 analysts)

buy

Avg. price target

$6.77+176.33%

  • Strong buy 2
  • Buy 1
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $10.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.22 vs $-0.24
Surprise
+8.33%

RXRX news

All RXRX news

Recursion Pharmaceuticals peers

Health Care sector
RXRX peer companies
CompanyPrice% ChgMarket capCompare
VIRVir Biotechnology Inc.8.39-5.41%$1.56Bvs RXRX
ALVOAlvotech4.12-3.96%$1.47Bvs RXRX
WWBWindward Bio Group AG24.29+1.15%$1.45Bvs RXRX
MESOMesoblast Limited ADR10.89-2.59%$1.41Bvs RXRX
IMCRImmunocore Holdings plc ADR26.41-0.83%$1.36Bvs RXRX
MAZEMaze Therapeutics Inc.31.37-3.27%$1.72Bvs RXRX
LYCALycia Therapeutics Inc.33.07+4.09%$1.72Bvs RXRX
REPLReplimune Group Inc.19.07-0.83%$1.81Bvs RXRX

Indexes, lists and sector

Recursion Pharmaceuticals stock FAQ

What is Recursion Pharmaceuticals's stock price today?

RXRX last traded at $2.45 as of Nov 20, 4:00 PM EST, down 9.93% on the day. Prices are delayed at least 15 minutes.

Who is Recursion Pharmaceuticals's CEO?

Dr. Najat Khan Ph.D. is the chief executive officer of Recursion Pharmaceuticals Inc. Class A, which has about 600 employees.

What is the RXRX 52-week high?

The 52-week high for RXRX is $5.24 and the 52-week low is $2.44. The stock is currently 53.2% below its high.

Compare RXRX